MiniMed Group Inc (NYSE: MMED) is a medical technology company that develops, manufactures, and markets diabetes management systems, including automated insulin delivery (AID) systems and smart multiple daily injection (Smart MDI) systems. Revenue comes from device sales across three categories: insulin pumps, consumables (infusion sets and reservoirs), and continuous glucose monitoring (CGM) sensors. The company operates globally, with international markets generating $1,586 million of the $2,265 million in net sales for the nine months ended January 23, 2026, representing 70% of total revenue. MiniMed was historically Medtronic plc's diabetes business and completed an IPO in March 2026, with Medtronic retaining approximately 90.03% of outstanding shares as of the filing date. The flagship product is the MiniMed 780G AID system. For the nine months ended January 23, 2026, net sales grew 14% year-over-year to $2,265 million, while the company reported a net loss attributable to the company of $148 million. R&D expense was $349 million for the same period.

Revenue model

Transactional product sales across three lines: insulin pumps (durable devices), consumables (recurring infusion sets and reservoirs requiring frequent replacement for uninterrupted AID system operation), and CGM sensors. Consumables and CGM generate recurring revenue as patients replace components on an ongoing basis. For Q3 FY2026 (three months ended January 23, 2026), pumps were $151 million, consumables $244 million, with CGM contributing to the remaining revenue mix.

Products and services

MiniMed 780G AID system (flagship), which integrates an insulin pump, consumable infusion sets and reservoirs, a CGM sensor, and a Smart Dosing algorithm. Simplera CGM sensor (launched in Europe in FY2025, launched in the U.S. in Q3 FY2026). Instinct CGM (launched in the U.S. in Q3 FY2026). Smart MDI system, which includes a Smart Insulin Pen, CGM sensor, and software applications for patients who prefer manual injection over pump-based delivery.

Customers and end markets

People with diabetes (PWD) who require insulin management, including those using AID systems and those preferring manual injection via Smart MDI systems. End market is the global insulin-dependent diabetes population. No customer concentration data disclosed in the filing excerpts.

Value-chain role

Vertically integrated medical device manufacturer: designs proprietary hardware (pumps, pens, sensors), manufactures consumables and durable devices, and sells directly to patients and through distribution channels. Also develops proprietary dosing algorithms (Smart Dosing software) embedded in devices. Recently separated from Medtronic and is transitioning to standalone operations, with transitional services agreements with Medtronic still in effect as of the filing date.

Geographic exposure

U.S. and international markets. For the nine months ended January 23, 2026, U.S. net sales were $679 million (30% of total) and international net sales were $1,586 million (70% of total). International organic revenue grew 10.9% for the same period. International pump sales grew 12% following the Simplera CGM launch in Europe in FY2025.

Source: SEC 10-Q, filed 2026-04-17

Industry: Surgical & Medical Instruments & Apparatus